Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer’s.
Roodeweg 222, Willemstad, Curaçao
Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer’s.
Roodeweg 222, Willemstad, Curaçao